Answers are grounded in this paper and cite their sources.
BACKGROUND: α-Pinene is a naturally occurring monoterpene that has attracted increasing interest for its potential effects on the central nervous system (CNS). This review critically evaluates preclinical evidence regarding its effects on neuroinflammation, oxidative stress, neurotrophic signaling, cellular injury, and behavioral outcomes. METHODS: A literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar from database inception to April 2026. Studies investigating CNS-related effects of α-pinene, including in vitro and in vivo experimental studies, were narratively synthesized according to biological mechanisms, experimental models, doses, administration routes, treatment duration, and outcomes. No formal risk-of-bias assessment or quantitative meta-analysis was performed. RESULTS: Preclinical evidence indicates that α-pinene is associated with attenuation of inflammatory signaling, particularly TLR4/MyD88/NF-κB-related responses, and reduction of oxidative stress accompanied by enhanced endogenous antioxidant defenses. Modulation of BDNF/TrkB/CREB-associated signaling has also been reported, although evidence is more limited and context-dependent. Additional studies suggest effects on apoptosis-related signaling, glial activation, inflammasome-associated pathways, JNK signaling, and endoplasmic reticulum stress. Behavioral studies report anxiolytic-like, cognitive, anticonvulsant, motor-protective, and analgesic effects in several experimental models. However, dose-response and pharmacokinetic-pharmacodynamic relationships remain insufficiently characterized, and some findings are model-dependent. CONCLUSION: Current evidence supports α-pinene as a biologically active monoterpene with CNS-related effects predominantly demonstrated in preclinical models. A single validated molecular mechanism, therapeutic dose range, or human CNS therapeutic window has not been established. Further independent replication, standardized dose-response studies, brain-exposure profiling, mechanistic validation, and long-term safety studies are required before clinical translation can be considered.
No takes yet. Share an insight, caveat, or question.
Rahimi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: